Sugi Predict

Sugi Predict / Compounds / SCHEMBL274346

SCHEMBL274346

SCHEMBL274346

CCOC(=O)c1cnc(Br)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 3/20 0.59
▸ DBF4 Q9UBU7 3/20 0.59
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ GAA P10253 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1519816 0.98 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1
Dioxane SCHEMBL21199902 0.91 CDC7 (0.51) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL21199901 0.87 CDC7 (0.48) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL16933028 0.84 CDC7 (0.60) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL286068 0.84 CDC7 (0.60) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL6476591 0.82 CDC7 (0.59) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL1646493 0.81 CDC7 (0.55) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL222203 0.81 SMN1; SMN2 (0.58) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL21963019 0.81 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1
SCHEMBL1912617 0.81 CDC7 (0.57) CDC7DBF4HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112939829-B Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2023-02-21 — — CN claimed
CN-112939829-A Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2021-06-11 — — CN claimed
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 — — US disclosed
EP-4727546-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE The Global Alliance for TB Drug Development, Inc. (US) 2026-04-22 — — EP disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 — — EP disclosed
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 — — US disclosed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 — — EP disclosed
EP-4676937-A1 METHODS OF SYNTHESIZING FLUORINATED MACROCYCLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-14 — — EP disclosed
EP-4665373-A2 SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF RS Oncology, LLC (US) 2025-12-24 — — EP disclosed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 — — US disclosed
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 — — US disclosed
US-6066639-A ANTITUMOR AGENTS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2000-05-23 — — US disclosed
EP-0904271-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1999-03-31 — — EP disclosed
WO-1997041115-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-11-06 — — WO disclosed
EP-0436199-B1 Cyclopropyl derivative lipoxygenase inhibitors ABBOTT LAB (US) 1994-08-03 — — EP disclosed
US-5120752-A N-(1-(20(3-pyridyloxy)phenyl)cyclopropyl) alkyl-N-hydroxyurea compounds, antiinflammatory agents ABBOTT LABORATORIES (US) 1992-06-09 — — US disclosed
EP-0436199-A1 Cyclopropyl derivative lipoxygenase inhibitors ABBOTT LABORATORIES (US) 1991-07-10 — — EP disclosed
US-4089865-A Certain thiazole compounds SYNTEX (U.S.A.) INC. (US) 1978-05-16 — — US disclosed
US-4077968-A ANTIINFLAMMATORY, ANTIRHEUMATIC, ANALGESIC, ANTILIPEMIC SHIONOGI & CO., LTD. (JA) 1978-03-07 — — US disclosed
US-4001421-A THIAZOLE CARDIOVASCULAR AGENTS SYNTEX (U.S.A.) INC. (US) 1977-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 CDC7 3101/4885DBF4 4204/4885HDAC3 12/4885
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 CDC7 4549/4885DBF4 4388/4885HDAC3 166/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 CDC7 710/4885DBF4 3545/4885HDAC3 426/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 CDC7 4122/4885DBF4 4772/4885HDAC3 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.